Hemostemix Inc. (CVE:HEM – Get Free Report) was down 5.6% during mid-day trading on Monday . The company traded as low as C$0.08 and last traded at C$0.09. Approximately 241,030 shares were traded during trading, a decline of 26% from the average daily volume of 327,134 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company’s 50 day simple moving average is C$0.10 and its 200 day simple moving average is C$0.11. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The stock has a market capitalization of C$15.39 million, a PE ratio of -3.15 and a beta of 1.03.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Best Aerospace Stocks Investing
- Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops
- Dividend Capture Strategy: What You Need to Know
- Nuclear Stocks Are Melting Down—Should Investors Panic?
- Growth Stocks: What They Are, What They Are Not
- Monday.com Opens Generational Opportunity With Manic Sell-Off
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
